Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30828884 | 0.86 | TGFBR1 (0.51) | TGFBR1PIK3CAP2RX7TSHR | |
| SCHEMBL30845788 | 0.85 | GLS (0.37) | TGFBR1KDM4EPIK3CAP2RX7 | |
| SCHEMBL2730806 | 0.79 | KDM4E (0.54) | KDM4ERXFP1 | |
| SCHEMBL10272003 | 0.77 | PTGS2 (0.53) | PTGS1PTGS2 | |
| SCHEMBL17169821 | 0.77 | PIK3CA (0.37) | PTGS2TGFBR1PIK3CAP2RX7HDAC4 | |
| SCHEMBL21033324 | 0.77 | PTGS1 (0.49) | PTGS1PTGS2TGFBR1KDM4ERXFP1 | |
| SCHEMBL29019469 | 0.76 | PTGS1 (0.47) | PTGS1PTGS2KDM4ERXFP1NAPRT | |
| SCHEMBL18506076 | 0.73 | MCHR1 (0.37) | PTGS1PTGS2TGFBR1 | |
| SCHEMBL12778716 | 0.73 | SCN5A (0.35) | TGFBR1 | |
| SCHEMBL20705103 | 0.73 | PTGS1 (0.53) | PTGS1PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | OPPILAN PHARMA LTD (GB) | 2021-06-03 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
| US-9023850-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2629614-B1 | NEMATOCIDAL SULFONAMIDES | DU PONT (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2629614-A1 | NEMATOCIDAL SULFONAMIDES | E.I. Du Pont De Nemours And Company (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20130190172-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012054233-A1 | NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190172-A1 | NEMATOCIDAL SULFONAMIDES | QSOX1, ARSA, NOX1 | PTGS1 304/4885PTGS2 995/4885TGFBR1 1623/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PTGS1 2236/4885PTGS2 3251/4885TGFBR1 1740/4885 |
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | VHL, FH, TPMT | PTGS1 1877/4885PTGS2 1607/4885TGFBR1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.